We thus analyzed the levels of several myeloid populations, including four different MDSC subsets, monocytes (evaluated as CD14+ cells) and PMN (evaluated as CD15+ cells), in the peripheral blood of BrM and GBM patients and compared them with a group of HD matched for sex and age. This evidence concerns the gene CD14 and glioblastoma.